Artivion SVP Jean Holloway sells 977 shares for $27,834 By Investing.com

Jean F. Holloway, Senior Vice President and General Counsel at ARTIVION, INC. (), sold 977 shares of the company’s common stock on August 12, 2026. The transactions totaled $27,834, with shares sold at a price of $28.49 each. The sale comes as the stock has posted a 9.4% gain over the past week, trading at $28.64 with a market capitalization of $1.38 billion.

Following this transaction, Ms. Holloway directly holds 184,118 shares of Artivion common stock. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value, though analysts maintain price targets ranging from $38 to $48 per share.

In other recent news, Artivion Inc. reported second-quarter revenue of $125.8 million, marking a 9% increase on a constant currency basis and surpassing Wall Street’s forecast of $120.06 million. The growth was driven by strong performances in stent grafts and On-X heart valves, although it was partially offset by softer BioGlue sales and increased spending linked to recent acquisitions. The company also achieved an adjusted EBITDA of $26.4 million, exceeding both Canaccord’s estimate of $21.6 million and the consensus of $21.7 million. Artivion’s acquisition of Endospan and the PMA approval for AMDS were significant developments contributing to the company’s positive outlook. Canaccord responded by raising its price target for Artivion to $39 from $36, while maintaining a Buy rating. The firm highlighted the second-quarter growth in On-X and Aortic Stent Grafts as key factors in this decision. Artivion has reiterated its fiscal 2026 guidance, indicating confidence in its future performance.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.